Abstracts tagged "Gene Expression"

Abstract Number: 1565 • 2016 ACR/ARHP Annual Meeting
Gene Modules Correlated with Disease Activity and Abatacept Treatment Identified with Weighted Gene Co-Expression Network Analysis of CD4+ T Cell Subsets of RA
Shuji Sumitomo¹, Yasuo Nagafuchi¹, Yumi Tsuchida¹, Haruka Tsuchiya¹, Mineto Ota¹, Kazuyoshi ishigaki², Shinichiro Nakachi¹, Rika Kato¹, Keiichi Sakurai¹, Norio Hanata¹, Shoko Tateishi³, Hiroko Kanda³, Akari Suzuki⁴, Yuta Kochi⁴, Keishi Fujio¹ and Kazuhiko Yamamoto¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, The Institute of Physical and Chemical Research (RIKEN), Yokohama, Japan, ³Department of Immunotherapy Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
Background/Purpose: Although there are several reports of transcriptome analysis of peripheral blood mononuclear cells (PBMC) in RA, analysis of detailed CD4+ subset and the effect…
Abstract Number: 2928 • 2016 ACR/ARHP Annual Meeting
Hypomethylation of an Intragenic Alternative Promoter Contributes to Impaired Treg Function in Rheumatoid Arthritis By Transcriptional Interference with Expression of the Treg-Specific Protein, Glycoprotein a Repetitions Predominant (GARP)
Alla Skapenko, Jan Leipe and Hendrik Schulze-Koops, Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany
Background/Purpose: The expression of Treg specific genes, such as the master transcription factor of Tregs, FoxP3 or the Treg specific surface molecule, glycoprotein A repetitions…
Abstract Number: 669 • 2016 ACR/ARHP Annual Meeting
RNA-Sequencing Reveals Sjogren’s Syndrome Anti-Ro Negative Patients Share Similar Pathways to Multiple Sclerosis Patients
Indra Adrianto¹, John Ice¹, Astrid Rasmussen², Courtney Montgomery¹, R. Hal Scofield¹, Gabriel Pardo¹, Kathy Sivils¹, Robert Axtell¹ and Christopher Lessard¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune disease characterized by autoantibodies to Ro and/or La proteins and lymphocytic infiltration into exocrine glands. Multiple sclerosis (MS)…
Abstract Number: 1571 • 2016 ACR/ARHP Annual Meeting
Altered Bioenergetics, Mitochondrial Function and Pro-Inflammatory Pathways in RA Synovium in Response to Tofacitinib
Carl Orr¹, Trudy McGarry², Monika Biniecka³, Jennifer McCormick⁴, Ursula Fearon⁵ and Douglas J. Veale¹, ¹Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ²St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ³St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ⁴Department of Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ⁵Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid arthritis (RA) is a chronic joint disease, characterised by synovial inflammation and destruction of articular cartilage/bone. The Janus-Kinase and Signal Transducer and Activator…
Abstract Number: 3117 • 2016 ACR/ARHP Annual Meeting
Development of Autoimmune Diseases and Genetic Predisposition in Children with Neonatal Lupus and Their Unaffected Siblings
Aaron Garza Romero¹, Peter M. Izmirly², Hannah C. Ainsworth³, Miranda Marion³, Carl Langefeld³, Robert Clancy⁴, Jill P. Buyon⁵ and Amit Saxena⁶, ¹Rheumatology, NYU School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Wake Forest School of Medicine, Winston-Salem, NC, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Medicine, New York University School of Medicine, New York, NY, ⁶Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Neonatal Lupus (NL) is a model of passively acquired autoimmunity conferred by exposure to maternal anti-Ro antibodies. This study was initiated to address the…
Abstract Number: 670 • 2016 ACR/ARHP Annual Meeting
Identification and Characterization of Sjogren’s Syndrome-Associated Genetic Variants in the IL12A and DDX6-CXCR5 Loci
Michelle L. Joachims¹, Indra Adrianto², Audrey Johnston², John Ice², Astrid Rasmussen³, Simon Bowman⁴, David M. Lewis⁵, Lida Radfar⁶, Roald Omdal⁷, Marie Wahren-Herlenius⁸, Ilias Alevizos⁹, Torsten Witte¹⁰, Roland Jonsson^11,12, Maureen Rischmueller^13,14, Patrick M. Gaffney², Judith A. James^2,15,16, Lars Rönnblom¹⁷, Elke Theander¹⁸, Nelson L. Rhodus¹⁹, Barbara M. Segal²⁰, R. Hal Scofield^2,16,21, Courtney G. Montgomery², Xavier Mariette²², Wan-Fai Ng²³, Gunnel Nordmark²⁴, Kathy L. Sivils^2,15 and Christopher J. Lessard^2,15, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ⁴Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁵Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁶Oral Diagnosis and Radiology Department, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁷Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁸Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁹Sjögren's Syndrome Clinic, National Institute of Dental and Craniofacial Research, Bethesda, MD, ¹⁰Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ¹¹Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ¹²Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ¹³Rheumatology, Queen Elizabeth Hospital, Adelaide, Australia, ¹⁴Rheumatology, University of Adelaide, Adelaide, Australia, ¹⁵Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁶Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁷Uppsala University, Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala, Sweden, ¹⁸Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Malmö, Sweden, ¹⁹Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁰Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ²¹US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ²²Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ²³Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²⁴Rheumatology, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune-mediated disease with hallmark features of dry eyes/mouth and autoantibodies. Genetic susceptibility to SS involves many loci, including the…
Abstract Number: 1638 • 2016 ACR/ARHP Annual Meeting
Antibody Mediated Immunity Drives Response to Methotrexate Treatment in Rheumatoid Arthritis Patients
Boel Brynedal¹, Helga Westerlind², Lasse Folkersen^3,4, Leonid Padyukov⁵, Nancy Vivar⁵, Anca I Catrina⁶, Lars Klareskog⁵ and Louise Berg⁵, ¹Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Karolinska, Sweden, ²Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark, ⁵Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden, ⁶Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Methotrexate (MTX) is the first line treatment for Rheumatoid Arthritis (RA) in Sweden, but one third of patients do not experience satisfying treatment response.…
Abstract Number: 3175 • 2016 ACR/ARHP Annual Meeting
Longitudinal Analysis of MMF Clinical, Molecular, and Immunohistochemistry (IHC) Responses Shows SSc Patients Lose Their Inflammatory Signature and Rebound upon Treatment Cessation
Diana Toledo¹, Monique Hinchcliff², Jaclyn Taroni¹, Tammara A. Wood³, Jennifer Franks³, Sanjiv Shah⁴, Rishi Agrawal⁴, Lauren Beussink-Nelson⁴, Mary A. Carns⁵, Sofia Podlusky⁶, Patricia Pioli⁷ and Michael Whitfield³, ¹Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ³Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Northwestern University, Chicago, IL, ⁵Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁶Rheumatology Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁷Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: We previously showed patients in the inflammatory subset were most likely to demonstrate improvement in modified Rodnan Skin Score (mRSS) during mycophenolate mofetil (MMF)…
Abstract Number: 800 • 2016 ACR/ARHP Annual Meeting
An Altered Cardiovascular System Development Gene Expression Signature in Skin is a Hallmark of Limited Cutaneous Systemic Sclerosis
Emma C. Derrett-Smith^1,2, Viktor Martyanov³, Cecilia B. Chighizola⁴, Pia Moinzadeh⁵, Korsa Khan⁶, Tammara A. Wood³, Pier Luigi Meroni⁷, David Abraham⁸, Voon H. Ong⁹, Michael Whitfield³ and Christopher Denton⁸, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ²Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Department of Clinical Sciences and Community Health, University of Milan, IRCCS Istituto Auxologico Italiano, Milano, Italy, ⁵Department of Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁶Centre For Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ⁷Rheumatology Department, University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁸Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁹Rheumatology, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Limited cutaneous SSc (lcSSc) is characterised by less extensive skin fibrosis but patients can develop major internal organ complications and vascular manifestations. Gene expression…
Abstract Number: 1665 • 2016 ACR/ARHP Annual Meeting
Validation of Germ Line Epigenetic Variants Associated with Psoriatic Disease
Remy Pollock¹, Laila Zaman¹, Vinod Chandran² and Dafna D Gladman³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Heritable epigenetic phenomena may play a role in the parent-of-origin effect observed in psoriasis and psoriatic arthritis (PsA). A previous epigenome-wide association study (EWAS)…
Abstract Number: 3220 • 2016 ACR/ARHP Annual Meeting
Distinct Single Cell Gene Expression Signatures of Monocyte Subsets Differentiate Between TNF-Alpha Inhibitor Treatment Response Groups in Rheumatoid Arthritis
Theresa L. Wampler Muskardin¹, Wei Fan², Zhongbo Jin³, Mark A. Jensen⁴, Jessica M. Dorschner³, Yogita Ghodke-Puranik³, Kerry Wright¹, John M. Davis III⁵, Eric L. Matteson¹, Clement Michet Jr.¹, Thomas G. Mason II⁶, Scott T. Persellin⁷, Daniel Schaffer¹, Betty Dicke¹, Danielle Vsetecka³ and Timothy B. Niewold⁸, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁴Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁶Division of Rheumatology - Department of Medicine, Mayo Clinic Rochester, Rochester, MN, ⁷Department of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁸Rheumatology and Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: In rheumatoid arthritis (RA), initiating effective treatment as soon as possible within the so-called therapeutic “window of opportunity” is the strategy, and remission is…
Abstract Number: 801 • 2016 ACR/ARHP Annual Meeting
Multi-Tissue Gene Expression Pathway Analysis of Emerging Therapeutics in a TGFβ Dependent Mouse Model of Systemic Sclerosis
Emma C. Derrett-Smith^1,2, Shiwen Xu³, Rachel K. Hoyles⁴ and Christopher Denton⁵, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ²Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Division of Medicine, Centre for Rheumatology and Connective tissue disease, University College London, London, United Kingdom, ⁴Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom
Background/Purpose: We have previously investigated the interplay between TGFβ, BMP, VEGF and endothelin in SSc using the TβRIIΔk-fib strain, a transgenic mouse model in…
Abstract Number: 1827 • 2016 ACR/ARHP Annual Meeting
Type I IFN Signature Low and High SLE Subjects with Moderate to Severe Disease Activity Have Distinct Gene Expression Signatures of Immunologic Pathways and Cell Types
Hao Liu¹, Brandon Higgs², William Rees³, Chris Morehouse⁴, Katie Streicher⁵, P Brohawn², G. Illei⁶ and K Ranade², ¹Translational Medicine, Medimmune, LLC, Gaithers, MD, ²MedImmune, Gaithersburg, MD, ³Translational Medicine, Medimmune, LLC, Gaithersburg, MD, ⁴Medimmune, LLC, Gaithers, MD, ⁵Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁶Medimmune, Gaithersburg, MD
Background/Purpose: Type I interferon (IFN) has been implicated in SLE pathogenesis, and the majority of subjects with SLE have elevated expression of type I IFN-inducible…
Abstract Number: 3230 • 2016 ACR/ARHP Annual Meeting
Genome-Wide Association Study Identifies Novel Sjögren’s Syndrome Risk Loci in the Regions of NAB1, TYK2, and PTTG1-mir146a
Christopher J. Lessard¹, Indra Adrianto¹, John Ice¹, Astrid Rasmussen², Kiely Grundahl³, Jennifer A. Kelly⁴, R. Hal Scofield¹, Simon Bowman⁵, Susan Lester⁶, Per Eriksson⁷, Maija-Leena Eloranta⁸, Johan G. Brun⁹, Lasse G. Goransson¹⁰, Erna Harboe¹⁰, Marika Kvarnström¹¹, Michael T. Brennan¹², James Chodosh¹³, Raj Gopalakrishnan¹⁴, Andrew J.W. Huang¹⁵, Pamela Hughes¹⁶, David M. Lewis¹⁷, Michael D. Rohrer¹⁸, Donald U. Stone¹⁹, Nelson L. Rhodus²⁰, Barbara M. Segal²¹, Lida Radfar²², A. Darise Farris²³, Joel M. Guthridge²⁴, Patrick M. Gaffney¹, Judith A. James¹, John B. Harley²⁵, Lars Rönnblom⁸, Juan-Manuel Anaya²⁶, Deborah S. Cunninghame-Graham²⁷, Timothy J. Vyse²⁸, Ilias Alevizos²⁹, Xavier Mariette³⁰, Roald Omdal¹⁰, Marie Wahren-Herlenius³¹, Torsten Witte³², Roland Jonsson³³, Maureen Rischmueller³⁴, Lindsey A. Criswell³⁵, Courtney G. Montgomery¹, Wan-Fai Ng³⁶, Gunnel Nordmark³⁷ and Kathy L. Sivils¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ⁴Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia, ⁷University Hospital, Rheumatology clinic, Linköping, Sweden, ⁸Uppsala University, Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala, Sweden, ⁹Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ¹⁰Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ¹¹Karolinska Institutet, Stockholm, Sweden, ¹²Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, ¹³Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁴Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁵Washington University,, St Louis, MO, ¹⁶Division of Oral and Maxillofacial Surgery, Department of Developmental and Surgical Science, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁷Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ¹⁸Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁹Dean McGee Eye Institute, Oklahoma City, OK, ²⁰Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ²¹Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ²²Oral Diagnosis and Radiology Department, University of Oklahoma College of Dentistry, Oklahoma City, OK, ²³Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK, ²⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁵Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Childrens Hospital, Cincinnati, OH, ²⁶Center for Autoimmune Diseases Research (CREA). School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bogotá, Colombia, ²⁷Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, ²⁸Division of Immunology, Infection and Inflammatory Disease, King’s College London, London, United Kingdom, ²⁹Sjögren's Syndrome Clinic, National Institute of Dental and Craniofacial Research, Bethesda, MD, ³⁰Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ³¹Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³²Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ³³Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ³⁴Rheumatology, University of Adelaide, Adelaide, Australia, ³⁵Division of Rheumatology, UCSF, San Francisco, CA, ³⁶Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³⁷Rheumatology, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden
Background/Purpose: Sjögren’s syndrome (SS) is a complex autoimmune disease with both environmental and genetic factors contributing to pathophysiology. The goal of this genome-wide association study…
Abstract Number: 802 • 2016 ACR/ARHP Annual Meeting
Whole Transcriptome Profiling through RNA Sequencing Reveals Differentially Expressed Sense-Antisense Gene Pairs in Patients with Systemic Sclerosis
Tobias Messemaker^1,2, Loubna Chadli³, Varshna Goelela³, Maaike Boonstra⁴, Annemarie Dorjee⁴, Stefan Andersen³, Harald Mikkers², Tom WJ Huizinga⁴, Zhenghui Li⁵, Guoshuai Cai⁵, Michael Whitfield⁶, René Toes⁷, Jamil Aarbiou³, Jeroen De Groot³, Jeska K. de Vries-Bouwstra⁴ and Fina Kurreeman⁴, ¹Department of Rheumagoloty, Leiden University Medical Center, Leiden, Netherlands, ²Department of Molecular cell Biology, Leiden University Medical Center, Leiden, Netherlands, ³Charles River Nederland B.V., Leiden, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁶Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of skin and multiple organs. Morbidity and mortality are high and pathogenesis is poorly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.